A digital future for value added medicines

Open letter to the Members of the European Parliament on the importance to sustain EU progress in fighting against antimicrobial resistance (AMR)

OPEN

Medicines for Europe Commentary on the Draft EMA regulatory science strategy 2025

Calls to action to improve access to value added medicines

Case Studies for Value Added Medicines. Unlocking the potential of patient-centric continuous innovation

Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA)

Medicines For Europe Country Specific Market Access Policies

Position paper on Best Procurement Practices

Open

IGBA position on identification of biological, including biosimilar medicines (2018 update of facts & figures)

Life Science Industry Coalition Position paper

Medicines For Europe